Perthera

Providing people with cancer & their oncologists with the best personalized and ranked #cancer treatment options through precision oncology. [email protected]

[Perthera @Perthera]

We’re delighted to present our new Chief Marketing Officer. She’s an industry veteran who’s excited about driving growth for #Perthera, a pioneer in #PrecisionOncology Decision Support. Read more about Jeanne at https://t.co/VisIZmQpb3

#PrecisionMedicine #MedTwitter #AI

[Perthera @Perthera]

It's been an amazing year for #Perthera at #ASCO24! Come to booth 37082 to learn about our patented Artificial Intelligence and how it can help physicians match cancer patients with individualized and optimized treatment options
#PrecisionMedicine #MedTwitter #OncTwitter #AI

[Perthera @Perthera]

It's that time of the year again for #ASCO24 Come find us at booth 37082, just north of the poster section! #ASCO24 #PrecisionMedicine #Perthera #ASCO2024 #MedTwitter #OncoAlert #OncTwitter #GIPOCS

[Perthera @Perthera]

Perthera Names HealthTech and Medical Marketing Veteran, Donna Tuths, as CEO https://t.co/k0FO4Qilfj via @ein_news

[Perthera @Perthera]

Part of the #Perthera dream team at #ASCO2023 and #PrecisionMedicine at its finest! 🧬⚕️ @MPishvaian @edikb @parbeloa @albertkelley @NancyTea13 #OncTwitter #OncoAlert #PancreaticCancer #MedTwitter

[Perthera @Perthera]

Come speak with @edikb as he presents our collective research at board 470 at the #ASCO2023 #PosterSession! @MPishvaian @HopkinsMedicine @GeorgeMasonU #GIPOCS #PanCan #PrecisionMedicine #Perthera

[Perthera @Perthera]

Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC) @ASCO. @MPishvaian @edikb @PanCAN #mPDAC #ASCO23 #Perthera #PrecisionMedicine

[Perthera @Perthera]

@edikb will be presenting our collective research at the #PosterSession at @ASCO today. Come find the team by board 470! #ASCO23 #ASCO2023

[Perthera @Perthera]

Powerful and personal opening statement by @ASCOPres @DrEricWiner yesterday, highlighting the cornerstones of effective cancer care. #ASCO2023 #ASCO23 #PrecisionMedicine

[Perthera @Perthera]

Today, on #NationalCancerSurvivorsDay, let's celebrate the incredible resilience and strength of those who have triumphed over #Cancer. Together, let's support #Survivors and raise awareness about the importance of ongoing research and the power of #PrecisionMedicine. #NCSD2023

[ASCO @ASCO]

Can patients with locally advanced rectal cancer safely avoid radiation and its often serious side effects? @PamelaKunzMD  breaks down new data from the PROSPECT trial presented at #ASCO23. See the study results https://t.co/EWMjGcRGZa

[Perthera @Perthera]

Come find the #Perthera team at Booth #26116 at @ASCO!
#ASCO2023 #ASCO23

[Jame Abraham, MD, FACP @jamecancerdoc]

Thank you @Surgeon_General for attending @ASCO #ASCO23 and addressing burnout among caregivers!

[Perthera @Perthera]

Nearly 50% of pts with mPDAC never receive a 2nd line of therapy for metastatic disease following frontline FFX or GA. Genomic alterations in the DDR pathway (e.g. BRCA1/2) are associated with increased progression-free survival (PFS) on ...👉 https://t.co/wAL7n7LC7e #ASCO23

[Perthera @Perthera]

Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC). https://t.co/wAL7n7LC7e Visit our poster session #ASCO23 @MPishvaian @edikb

[Perthera @Perthera]

At ASCO '23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for... https://t.co/pmxqXWY5nn